<DOC>
	<DOCNO>NCT02911311</DOCNO>
	<brief_summary>Panretinal photocoagulation ( PRP ) standard treatment Proliferative diabetic retinopathy ( PDR ) since Diabetic Retinopathy Study demonstrate benefit nearly 40 year ago , PRP inevitable adverse effect visual function . Intravitreal injection vascular endothelial growth factor ( VEGF ) induce short-term regression retinal neovascularization ( NV ) . The purpose ass compare efficacy safety intravitreal injection conbercept PRP .</brief_summary>
	<brief_title>Conbercept vs Panretinal Photocoagulation Management Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>Proliferative diabetic retinopathy ( PDR ) lead cause vision loss patient diabetes mellitus , initial manifestation PDR retinal neovascularization disc elsewhere.Panretinal photocoagulation ( PRP ) standard treatment PDR since Diabetic Retinopathy Study demonstrate benefit nearly 40 year ago , PRP inevitable adverse effect visual function include peripheral visual field defect , night vision loss , loss contrast sensitivity.Recent evidence indicate anti-vascular endothelial growth factor ( VEGF ) treatment reduce severity delay progression DR.However , impact treatment visual function effect anti-VEGF agent retinal neovascularization compare PRP remain unclear . It possible long-acting anti-VEGF agent conbercept . So design study prospective randomize control trial Intravitreal injection conbercept versus PRP PDR.Primary outcome change BCVA screen 12 month study eye measure ETDRS letter score 4</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>1 . Participants either sex age 18 year . 2 . Diagnosis diabetes mellitus ( type 1 2 ) . 3 . Bestcorrected visual acuity ( BCVA ) study eye well equal 30 Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter 4 . PDR evidence previous PRP . 5 . Media clarity , pupillary dilation participant cooperation sufficient adequate fundus photograph . 1. glycated haemoglobin ( HbA1c ) level 10 % ; 2 . Blood pressure &gt; 180/100 mmHg 3 . Myocardial infarction , acute cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 6 month 4. dialysis renal transplant 5 . Systemic antiVEGF proVEGF treatment within 6 month prior randomization 6 . For woman childbearing potential : pregnant lactate intend become pregnant within next 3 year 7 . Traction retinal detachment involve macula 8 . Exam evidence neovascularization angle 9 . History major ocular surgery anticipate within next 6 month follow randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>conbercept</keyword>
	<keyword>anti-VEGF agent</keyword>
	<keyword>panretinal photocoagulation</keyword>
</DOC>